Novo Nordisk sales and marketing update

Novo Nordisk said it will no longer market Tresiba insulin degludec in Germany after failing to agree on a price with Germany’s Statutory Health Insurance Funds Association (GKV-Spitzenverband). The company sells a daily dose of Tresiba for around EUR2.50 ($2.77), and GKV-Spitzenverband offered less than EUR1 ($1.11) per day. ...